MeVis Medical Solutions AG

Legal Proceedings Report • Jul 8, 2008

News Details

Corporate | 8 July 2008 09:14

EU breast cancer research project awarded to MeVis Medical Solutions

MeVis Medical Solutions AG / Miscellaneous

Release of a Corporate News, transmitted by DGAP - a company of EquityStory
AG.
The issuer / publisher is solely responsible for the content of this announcement.

---

EU breast cancer research project awarded:
MeVis Medical Solutions demonstrating innovativeness

• Improved early detection and diagnostics for breast cancer
• Sole commercial partner in the EU project
• MeVis Group to receive funding of around one million euros

Bremen, July 8, 2008. MeVis Medical Solutions AG [ISIN: DE000A0LBFE4] has
been awarded a role in an innovative breast cancer research project by the
European Union: On behalf of the European Institute for Biomedical Imaging
Research (EIBIR), the Bremen-based specialist in disease-oriented software
solutions in image-based medical technology will be working on further
improvements to the early detection of and diagnostics for breast cancer.

MeVis Medical Solutions is the only commercial partner in this newly
established syndicate, which comprises a further seven leading
international university and clinic facilities in Europe alongside the
non-profit research institute MeVis Research. All told, the MeVis Group
will be receiving funding of around one million euros towards its
involvement in the 'HAMAM' project, which will have a duration of 36
months. 'We are pleased to have been able to convince EIBIR of the merits
of this research project,' says Dr. Carl J.G. Evertsz, CEO of MeVis Medical
Solutions. 'Via this project, we will be able to show once more - this time
at a European level - what top innovative performance in the breast care
segment means and demonstrate our innovativeness and technological
leadership in image-based medical technology.' The Bremen-based company has
previously successfully completed the EU SCREEN and SCREEN-TRIAL breast
cancer projects.

The new project aims to consolidate all imaging processes in a single
workstation. This makes it possible to overcome the barriers resulting from
the hitherto isolated use of the imaging processes available. At the same
time, a comprehensive database will be established to supply medical
practitioners with additional information for diagnostic purposes. The
system uses certain algorithms to evaluate the information gained on the
patient during medical examinations and recommends further imaging
processes on this basis. This multimodal workstation can be subsequently
utilized on a cross-vendor basis, meaning that all available equipment can
be connected.

'Uniting the various imaging processes in a single system is a
revolutionary step, which not only facilitates medical practitioners’ work
but also makes a decisive contribution to successful breast cancer early
detection and diagnostics,' explains Evertsz. 'The automatic process
management system is a true innovation as it offers medical practitioners
recommendations for further appropriate procedures. MeVis Medical
Solutions will be contributing its proprietary software development
platform 'MeVisAP' for the duration of the research project as a basis for
developing the work station and the software solutions for the various
imaging processes.

The most modern forms of early detection and diagnostics are available for
breast cancer. New kinds of imaging processes, such as 3D ultrasonics and
tomosynthesis, supplement the established methods. Explains Evertsz: 'What
is decisive is for all available applications to be used efficiently for
the benefit of the patients and to ready these far-reaching improvements to
early detection and diagnostics for the market as quickly as possible.'

MeVis Medical Solutions AG is one of the world’s leading independent
producers of software products for image-based medical technology,
particularly digital radiology. Over the past few years, there has been an
enormous increase in the complexity and volume of medical image data
derived from digital imaging processes such as computer tomography (CT) and
magnetic resonance tomography (MRT). MeVis products analyze and process
this data in such a way as to provide medical practitioners with crucial
information for early detection, diagnosis and intervention of cancer- and
pulmonary diseases as well as neurological diseases. The Company develops
its software solutions in close consultation with the world’s leading
medical experts and original equipment makers (OEMs) in the medical
technology sector and primarily markets this software via these OEM
partnerships.

Company contact: MeVis Medical Solutions AG, Dr. Kai Holtmann,
Tel: +49 421 22495-63, E-mail: kai.holtmann@mevis.de

Press Contact: HOSCHKE & CONSORTEN Public Relations GmbH, Fabian Lorenz,
Grit Pauli, Tel: +49 40 3690 50-56 / -31, E-mail: f.lorenz@hoschke.de;
g.pauli@hoschke.de

08.07.2008 Financial News transmitted by DGAP

Language: English
Issuer: MeVis Medical Solutions AG
Universitätsallee 29
28359 Bremen
Deutschland
Phone: +49 421 330 74-0
Fax: +49 421 330 74-50
E-mail: ir@mevis.de
Internet: http://www.mevis.de
ISIN: DE000A0LBFE4
WKN: A0LBFE
Listed: Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr
in Berlin, München, Düsseldorf, Stuttgart

End of News DGAP News-Service

---